Tevogen Bio Holdings Inc. has announced the development of the alpha version of PredicTcell™, a proprietary machine learning model created in collaboration with Microsoft and Databricks. This model is designed to significantly expedite target analysis in immunotherapy research, potentially reducing drug development costs by billions. The announcement aligns with the U.S. government's AI Action Plan, which emphasizes rapid scientific AI innovation in the healthcare sector. As of now, Tevogen has not specified if these research results have been formally presented at any scientific conferences or publications.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.